The Experts below are selected from a list of 76896 Experts worldwide ranked by ideXlab platform
Karin Säljö - One of the best experts on this subject based on the ideXlab platform.
-
HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives
Scientific Reports, 2017Co-Authors: Karin Säljö, Angela Barone, Johan Mölne, Lennart Rydberg, Susann Teneberg, Michael E. BreimerAbstract:One prerequisite for a successful clinical outcome of human pluripotent stem cell (hPSC) based therapies is immune compatibility between grafted cells/Tissue and recipient. This study explores immune determinants of human embryonic stem cell lines (hESC) and induced human pluripotent stem cell (hiPSC) lines and hepatocyte- and cardiomyocyte-like cells derived from these cells. HLA class I was expressed on all pluripotent hPSC lines which upon differentiation into hepatocyte-like cells was considerably reduced in contrast to cardiomyocyte-like cells which retained class I Antigens. No HLA class II Antigens were found in the pluripotent or differentiated cells. Histo-blood group carbohydrate Antigens SSEA-3/SSEA-4/SSEA-5, Globo H, A, Le^x/Le^y and sialyl-lactotetra were expressed on all hPSC lines. Blood group AB(O)H Antigen expression was in accordance with ABO genotype. Interestingly, only a subpopulation of A1O1 cells expressed A. During differentiation of hPSC, some histo-blood group Antigens showed congruent alteration patterns while expression of other Antigens differed between the cell lines. No systematic difference in the hPSC cell surface Tissue Antigen expression was detected. In conclusion, hPSC and their derivatives express cell surface Antigens that may cause an immune rejection. Furthermore, Tissue Antigen expression must be established for each individual stem cell line prior to clinical application.
-
Expression of Tissue Antigens in Human Pluripotent Stem Cells and Alterations During Differentiation Potential application in regenerative medicine for treatment of terminal cell and organ failure
2017Co-Authors: Karin SäljöAbstract:The major limiting factor in the treatment of patients with end-stage organ failure is the insufficient number of human organs available for transplantation. An unlimited access to human cells, Tissues and organs would also open up possibilities to treat several chronic diseases, such as diabetes, neurological and cardiovascular diseases, affecting millions of patients worldwide. Cells and Tissues derived from human pluripotent stem cells (hPSC) could potentially fulfill these ambitions. However, there are several biomedical barriers to overcome before this can be a clinical reality. One of the most important concerns is the immunogenicity of the conceivable cell or Tissue grafts derived from hPSC when exposed to a non-self recipient. This thesis explores the expression of immunogenic Tissue HLA and blood group Antigens in several hPSC cell lines and their derivatives. This characterization was performed by several complementary analytical techniques, such as flow cytometry, immunohistochemistry, PCR, as well as biochemical characterization of glycosphingolipid molecular structures and protein bound Antigen composition. The results demonstrate that pluripotent stem cells express various cell surface immunodeterminants including HLA, AB(O)H and related histo-blood group Antigens. Moreover, we identified significant alterations of Antigen expression patterns during endodermal, mesodermal and ectodermal differentiation. Consequently, our results indicate that all hPSC-derived cells intended for clinical applications should be characterized regarding their individual Tissue Antigen profile in accordance with the standard selection criteria used in allotransplantation. Furthermore, we identified a novel cell surface marker of undifferentiated stem cells, sialyl-lactotetra, which can be used as a verification and selection tool for pluripotency, as well as a potential exclusion measure in heterogeneously differentiated cell cultures to prevent tumor formation. In conclusion, this thesis adds new knowledge regarding cell surface Antigen expression in hPSC of relevance both for basic science and for future clinical applications within transplantation and regenerative medicine.
Michael E. Breimer - One of the best experts on this subject based on the ideXlab platform.
-
HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives
Scientific Reports, 2017Co-Authors: Karin Säljö, Angela Barone, Johan Mölne, Lennart Rydberg, Susann Teneberg, Michael E. BreimerAbstract:One prerequisite for a successful clinical outcome of human pluripotent stem cell (hPSC) based therapies is immune compatibility between grafted cells/Tissue and recipient. This study explores immune determinants of human embryonic stem cell lines (hESC) and induced human pluripotent stem cell (hiPSC) lines and hepatocyte- and cardiomyocyte-like cells derived from these cells. HLA class I was expressed on all pluripotent hPSC lines which upon differentiation into hepatocyte-like cells was considerably reduced in contrast to cardiomyocyte-like cells which retained class I Antigens. No HLA class II Antigens were found in the pluripotent or differentiated cells. Histo-blood group carbohydrate Antigens SSEA-3/SSEA-4/SSEA-5, Globo H, A, Le^x/Le^y and sialyl-lactotetra were expressed on all hPSC lines. Blood group AB(O)H Antigen expression was in accordance with ABO genotype. Interestingly, only a subpopulation of A1O1 cells expressed A. During differentiation of hPSC, some histo-blood group Antigens showed congruent alteration patterns while expression of other Antigens differed between the cell lines. No systematic difference in the hPSC cell surface Tissue Antigen expression was detected. In conclusion, hPSC and their derivatives express cell surface Antigens that may cause an immune rejection. Furthermore, Tissue Antigen expression must be established for each individual stem cell line prior to clinical application.
Angela Barone - One of the best experts on this subject based on the ideXlab platform.
-
HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives
Scientific Reports, 2017Co-Authors: Karin Säljö, Angela Barone, Johan Mölne, Lennart Rydberg, Susann Teneberg, Michael E. BreimerAbstract:One prerequisite for a successful clinical outcome of human pluripotent stem cell (hPSC) based therapies is immune compatibility between grafted cells/Tissue and recipient. This study explores immune determinants of human embryonic stem cell lines (hESC) and induced human pluripotent stem cell (hiPSC) lines and hepatocyte- and cardiomyocyte-like cells derived from these cells. HLA class I was expressed on all pluripotent hPSC lines which upon differentiation into hepatocyte-like cells was considerably reduced in contrast to cardiomyocyte-like cells which retained class I Antigens. No HLA class II Antigens were found in the pluripotent or differentiated cells. Histo-blood group carbohydrate Antigens SSEA-3/SSEA-4/SSEA-5, Globo H, A, Le^x/Le^y and sialyl-lactotetra were expressed on all hPSC lines. Blood group AB(O)H Antigen expression was in accordance with ABO genotype. Interestingly, only a subpopulation of A1O1 cells expressed A. During differentiation of hPSC, some histo-blood group Antigens showed congruent alteration patterns while expression of other Antigens differed between the cell lines. No systematic difference in the hPSC cell surface Tissue Antigen expression was detected. In conclusion, hPSC and their derivatives express cell surface Antigens that may cause an immune rejection. Furthermore, Tissue Antigen expression must be established for each individual stem cell line prior to clinical application.
Susann Teneberg - One of the best experts on this subject based on the ideXlab platform.
-
HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives
Scientific Reports, 2017Co-Authors: Karin Säljö, Angela Barone, Johan Mölne, Lennart Rydberg, Susann Teneberg, Michael E. BreimerAbstract:One prerequisite for a successful clinical outcome of human pluripotent stem cell (hPSC) based therapies is immune compatibility between grafted cells/Tissue and recipient. This study explores immune determinants of human embryonic stem cell lines (hESC) and induced human pluripotent stem cell (hiPSC) lines and hepatocyte- and cardiomyocyte-like cells derived from these cells. HLA class I was expressed on all pluripotent hPSC lines which upon differentiation into hepatocyte-like cells was considerably reduced in contrast to cardiomyocyte-like cells which retained class I Antigens. No HLA class II Antigens were found in the pluripotent or differentiated cells. Histo-blood group carbohydrate Antigens SSEA-3/SSEA-4/SSEA-5, Globo H, A, Le^x/Le^y and sialyl-lactotetra were expressed on all hPSC lines. Blood group AB(O)H Antigen expression was in accordance with ABO genotype. Interestingly, only a subpopulation of A1O1 cells expressed A. During differentiation of hPSC, some histo-blood group Antigens showed congruent alteration patterns while expression of other Antigens differed between the cell lines. No systematic difference in the hPSC cell surface Tissue Antigen expression was detected. In conclusion, hPSC and their derivatives express cell surface Antigens that may cause an immune rejection. Furthermore, Tissue Antigen expression must be established for each individual stem cell line prior to clinical application.
Lennart Rydberg - One of the best experts on this subject based on the ideXlab platform.
-
HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives
Scientific Reports, 2017Co-Authors: Karin Säljö, Angela Barone, Johan Mölne, Lennart Rydberg, Susann Teneberg, Michael E. BreimerAbstract:One prerequisite for a successful clinical outcome of human pluripotent stem cell (hPSC) based therapies is immune compatibility between grafted cells/Tissue and recipient. This study explores immune determinants of human embryonic stem cell lines (hESC) and induced human pluripotent stem cell (hiPSC) lines and hepatocyte- and cardiomyocyte-like cells derived from these cells. HLA class I was expressed on all pluripotent hPSC lines which upon differentiation into hepatocyte-like cells was considerably reduced in contrast to cardiomyocyte-like cells which retained class I Antigens. No HLA class II Antigens were found in the pluripotent or differentiated cells. Histo-blood group carbohydrate Antigens SSEA-3/SSEA-4/SSEA-5, Globo H, A, Le^x/Le^y and sialyl-lactotetra were expressed on all hPSC lines. Blood group AB(O)H Antigen expression was in accordance with ABO genotype. Interestingly, only a subpopulation of A1O1 cells expressed A. During differentiation of hPSC, some histo-blood group Antigens showed congruent alteration patterns while expression of other Antigens differed between the cell lines. No systematic difference in the hPSC cell surface Tissue Antigen expression was detected. In conclusion, hPSC and their derivatives express cell surface Antigens that may cause an immune rejection. Furthermore, Tissue Antigen expression must be established for each individual stem cell line prior to clinical application.